ProfileGDS5678 / 1426691_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 44% 44% 47% 38% 33% 48% 55% 47% 59% 47% 53% 43% 45% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.030943
GSM967853U87-EV human glioblastoma xenograft - Control 23.0292744
GSM967854U87-EV human glioblastoma xenograft - Control 33.0269944
GSM967855U87-EV human glioblastoma xenograft - Control 43.0610747
GSM967856U87-EV human glioblastoma xenograft - Control 52.8218338
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8368233
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2266448
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3666255
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0895747
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5504759
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1053347
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2564153
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0085943
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0523145